These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 16800411

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S, Olson M, van Staa TP.
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R, Blackhouse G, Adachi J.
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [Abstract] [Full Text] [Related]

  • 24. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT, Trinh H, Safi W.
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [Abstract] [Full Text] [Related]

  • 25. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
    Curtis JR, Westfall AO, Allison J, Freeman A, Kovac SH, Saag KG.
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):710-8. PubMed ID: 16498575
    [Abstract] [Full Text] [Related]

  • 26. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS.
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P.
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
    Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D.
    J Bone Miner Metab; 2007 Jan; 25(2):105-13. PubMed ID: 17323180
    [Abstract] [Full Text] [Related]

  • 33. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway.
    Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ.
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):297-304. PubMed ID: 22237942
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacologic therapy for the treatment and prevention of osteoporosis.
    McClung B, McClung M.
    Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658
    [Abstract] [Full Text] [Related]

  • 36. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Osteoporosis medication and reduced mortality risk in elderly women and men.
    Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1006-14. PubMed ID: 21289270
    [Abstract] [Full Text] [Related]

  • 40. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
    Martens MG, Shaw H.
    South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.